Pandemic Preparedness
Found 9 free book(s)
NOXXON ANNOUNCES THREE ADDITIONAL CLINICAL …
www.tmepharma.comthe COVID-19 pandemic. Along with the hospitals in Mannheim, Essen and Bonn, which have been participating in the recruitment of patients for the study since mid-2019, NOXXON will also collaborate with investigators at three additional hospitals in …
NOXXON PROVIDES UPDATE ON TIMING FOR UPCOMING …
www.tmepharma.comAram Mangasarian, CEO of NOXXON commented: "The effects of the COVID-19 pandemic continue to impact the healthcare industry in many areas, including the most essential ones like manufacturing supply chains. The NOX-A12 studies in pancreatic and brain cancer are our key clinical programs; the pancreas
NOXXON ENROLLS FIRST PATIENT IN THE SECOND DOSE …
www.tmepharma.comthe timely completion of the study under the challenging conditions of the COVID-19 pandemic, we are currently preparing the inclusion of three additional clinical sites to increase recruitment capacity.
NOXXON ENROLLS FIRST PATIENT IN THE HIGH DOSE …
www.tmepharma.comFeb 15, 2021 · pandemic. Six months of data from the second and third cohorts of patients should be available at end-Q2 2021 and end-Q3 2021, respectively,” he concluded. For more information, please contact: NOXXON Pharma N.V. Aram Mangasarian, Ph.D., Chief Executive Officer Tel. +49 (0) 30 726247 0 amangasarian@noxxon.com Trophic Communications
Annual Report 2021 - tmepharma.com
www.tmepharma.comNOXXON Pharma N.V.
Annual Shareholder’s Meeting - tmepharma.com
www.tmepharma.com2 AGENDA 1. Opening 2. Annual Accounts 2020 a. Discussion of the annual report 2020 (discussion) b. Discussion of Application of the remuneration for members of the board of directors (discussion)
TME Pharma N.V. Amsterdam, The Netherlands Annual Report …
www.tmepharma.comdiscussion with the FDA enabled TME Pharma to prepare an Investigational New Drug (IND) application that fits with the requirements of the US regulator in areas where there has been recent evolution in recommendations by the FDA’s Oncology Center of Excellence, such as the selection of the appropriate therapeutic dose of new oncology drugs.
NOXXON REPORTS 2021 FINANCIAL RESULTS - TME Pharma
www.tmepharma.comTo prepare for future clinical trials necessary to secure the regulatory approval of NOX-A12, NOXXON has made investment commitments for the manufacturing of drug supply for clinical trials. The company’s long-term strategic plans now include the following clinical trials, by indication, for NOX-A12: NOX-A12 + radiotherapy in Brain Cancer:
TME PHARMA PUBLISHES 2023 FINANCIAL RESULTS AND …
www.tmepharma.comPharma to prepare an Investigational New Drug (IND) application that fits with the requirements of the US regulator in areas where there has been recent evolution in recommendations by the FDA’s Oncology Center of Excellence, such as the selection of the appropriate therapeutic dose of new oncology drugs.